Budget Impact Analysis of the FreeStyle Libre Flash Continuous Glucose Monitoring System® in Patients with Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus with Multiple Daily Insulin Injections in Argentina

Alfredo Palacios, Federico Rodriguez-Cairoli (), Dario Balan (), Carlos Rojas-Roque (), Carolina Moreno-López (), Barbara Braun (), Federico Augustovski (), Andrés Pichon-Riviere () and Ariel Bardach ()
Additional contact information
Federico Rodriguez-Cairoli: Institute for Clinical Effectiveness and Health Policy (IECS)
Dario Balan: Institute for Clinical Effectiveness and Health Policy (IECS)
Carlos Rojas-Roque: Institute for Clinical Effectiveness and Health Policy (IECS)
Carolina Moreno-López: Institute for Clinical Effectiveness and Health Policy (IECS)
Barbara Braun: Sanatorio de la Trinidad Palermo
Federico Augustovski: Institute for Clinical Effectiveness and Health Policy (IECS)
Andrés Pichon-Riviere: Institute for Clinical Effectiveness and Health Policy (IECS)
Ariel Bardach: Institute for Clinical Effectiveness and Health Policy (IECS)
Authors registered in the RePEc Author Service: Carlos Rojas Roque

Applied Health Economics and Health Policy, 2023, vol. 21, issue 4, No 9, 637-650

Abstract: Abstract Objective To estimate the budget impact of the potential coverage of FreeStyle Libre Flash Continuous Glucose Monitoring System (FSL) for glycemia monitoring in all type 1 diabetes mellitus (T1DM) patients and in those with type 2 diabetes mellitus (T2DM) with multiple daily insulin injections, from the social security and the private third-party payer’s perspective in Argentina. Methods A budget impact model was developed to estimate the cost difference between the self-monitoring of blood glucose (standard of care) and FSL over 5 years. Input parameters were retrieved from local literature complemented by expert opinion. Health care costs were estimated by a micro-costing approach and reported in USD as of April 2022 (1 USD = 113.34 Argentine pesos). One-way sensitivity and scenario analyses were conducted. Results From a social security third-party payer perspective, the incorporation of FSL was associated with net savings per member per month (PMPM) of $0.026 (Year 1) to $0.097 (Year 5) and net savings PMPM of $0.002 (Year 1) to $0.008 (Year 5) for T1DM and T2DM patients, respectively. Similar findings are reported from the private third-party payer perspective. The budget impact results were more sensitive to the acquisition costs of the FSL and test strips. Conclusion The potential coverage of FSL in patients with T1DM and T2DM with multiple daily insulin injections could be associated with small financial savings considering current technology acquisition costs (FSL and test strips) for social security and the private sector third-party payers in Argentina.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40258-023-00800-0 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:21:y:2023:i:4:d:10.1007_s40258-023-00800-0

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-023-00800-0

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().